NCT07259304

Brief Summary

This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young adult cancer survivors. Researchers also hope to learn how social relationships change after a cancer diagnosis, and how these changes might impact important health behaviors. The information provided may help researchers learn more about better ways to support young cancer patients in the future through interventions that help maintain good social relationships and health levels of physical activity.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
20mo left

Started Nov 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress73%
Nov 2021Dec 2027

First Submitted

Initial submission to the registry

October 14, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

November 24, 2021

Completed
4 years until next milestone

First Posted

Study publicly available on registry

December 2, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

December 2, 2025

Status Verified

November 1, 2025

Enrollment Period

5.1 years

First QC Date

October 14, 2021

Last Update Submit

November 20, 2025

Conditions

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Central Nervous System NeoplasmClinical Stage I Cutaneous Melanoma AJCC v8Clinical Stage IA Cutaneous Melanoma AJCC v8Clinical Stage IB Cutaneous Melanoma AJCC v8Clinical Stage II Cutaneous Melanoma AJCC v8Clinical Stage IIA Cutaneous Melanoma AJCC v8Clinical Stage IIB Cutaneous Melanoma AJCC v8Clinical Stage IIC Cutaneous Melanoma AJCC v8Clinical Stage III Cutaneous Melanoma AJCC v8Hodgkin LymphomaMalignant Bone NeoplasmMalignant Brain NeoplasmMalignant Solid NeoplasmMalignant Testicular NeoplasmNon-Hodgkin LymphomaPathologic Stage I Cutaneous Melanoma AJCC v8Pathologic Stage IA Cutaneous Melanoma AJCC v8Pathologic Stage IB Cutaneous Melanoma AJCC v8Pathologic Stage II Cutaneous Melanoma AJCC v8Pathologic Stage IIA Cutaneous Melanoma AJCC v8Pathologic Stage IIB Cutaneous Melanoma AJCC v8Pathologic Stage IIC Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Prognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Stage I Cervical Cancer AJCC v8Stage I Colorectal Cancer AJCC v8Stage I Differentiated Thyroid Gland Carcinoma AJCC v8Stage I Ovarian Cancer AJCC v8Stage I Thyroid Gland Medullary Carcinoma AJCC v8Stage I Uterine Corpus Cancer AJCC v8Stage IA Cervical Cancer AJCC v8Stage IA Ovarian Cancer AJCC v8Stage IA Uterine Corpus Cancer AJCC v8Stage IA1 Cervical Cancer AJCC v8Stage IA2 Cervical Cancer AJCC v8Stage IB Cervical Cancer AJCC v8Stage IB Ovarian Cancer AJCC v8Stage IB Uterine Corpus Cancer AJCC v8Stage IB1 Cervical Cancer AJCC v8Stage IB2 Cervical Cancer AJCC v8Stage IC Ovarian Cancer AJCC v8Stage II Cervical Cancer AJCC v8Stage II Colorectal Cancer AJCC v8Stage II Differentiated Thyroid Gland Carcinoma AJCC v8Stage II Ovarian Cancer AJCC v8Stage II Thyroid Gland Medullary Carcinoma AJCC v8Stage II Uterine Corpus Cancer AJCC v8Stage IIA Cervical Cancer AJCC v8Stage IIA Colorectal Cancer AJCC v8Stage IIA Ovarian Cancer AJCC v8Stage IIA1 Cervical Cancer AJCC v8Stage IIA2 Cervical Cancer AJCC v8Stage IIB Cervical Cancer AJCC v8Stage IIB Colorectal Cancer AJCC v8Stage IIB Ovarian Cancer AJCC v8Stage IIC Colorectal Cancer AJCC v8Stage III Cervical Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Differentiated Thyroid Gland Carcinoma AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Thyroid Gland Medullary Carcinoma AJCC v8Stage III Uterine Corpus Cancer AJCC v8Stage IIIA Cervical Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8Stage IIIA1 Ovarian Cancer AJCC v8Stage IIIA2 Ovarian Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIB Ovarian Cancer AJCC v8Stage IIIB Uterine Corpus Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Stage IIIC Uterine Corpus Cancer AJCC v8Stage IIIC1 Uterine Corpus Cancer AJCC v8Stage IIIC2 Uterine Corpus Cancer AJCC v8

Outcome Measures

Primary Outcomes (7)

  • Rate of Change in trajectories of social health

    Social health variables include the number, frequency and duration of hospitalizations, specifics of cancer diagnosis (i.e., stage at diagnosis, pertinent histology, recurrence or progression of disease), chemotherapy type, surgery related to cancer diagnosis, radiation field, immunotherapy type, and other relevant therapies related to cancer treatment. Changes in above variables will be measured using latent growth curve models to measure latent intercept (initial level), and the latent slope (rate of change) of social health variables during the course of therapy.

    Baseline up to 1 year

  • Rate of Change in trajectories of physical activity

    Changes will be measured using latent growth curve models to measure latent intercept (initial level) and the latent slope (rate of change) of physical activity during the course of therapy.

    Baseline up to 1 year

  • Rate of Change in trajectories of quality of life

    Changes will be measured using latent growth curve models to measure latent intercept (initial level) and the latent slope (rate of change) of quality of life during the course of therapy.

    Baseline up to 1 year

  • Moderation by gender

    Will conduct multi-group analyses by the categories of study moderators (e.g., gender, race/ethnicity, socioeconomic status \[SES\], health status). The strengths of group-specific pathways to link social health and activity behaviors to quality of life will be compared using the chi-square (χ2) difference test of model fit. The log-likelihood values with (versus \[vs.\] without) the equality constraints on the group-specific pathways to determine if the strength of associations estimated in the models significantly differ by the groups of each moderator (e.g., gender: female vs. male).

    Up to 1 year

  • Moderation effect of race/ethnicity

    Moderation effect is analyzed by the interaction between the independent variable (X), and the moderator variable (Y) in a regression model, where the endpoint is the dependent variable (Z). Moderation effect is the endpoint itself, indicated by the significance of the interaction term's regression coefficient (B3), which shows how the relationship between X and Y changes depending on the level of Z. 'X' is social health, physical activity, and quality of life. 'Y' is race/ethnicity. 'Z' is moderation effect. The strengths of group-specific pathways to link social health and activity behaviors to quality of life will be compared using the chi-square (χ2) difference test of model fit.

    Up to 1 year

  • Moderation effect of Socio-Economic Status (SES)

    Moderation effect is analyzed by the interaction between the independent variable (X), and the moderator variable (Y) in a regression model, where the endpoint is the dependent variable (Z). Moderation effect is the endpoint itself, indicated by the significance of the interaction term's regression coefficient (B3), which shows how the relationship between X and Y changes depending on the level of Z. 'X' is social health, physical activity, and quality of life. 'Y' is socio-economic status. 'Z' is moderation effect. The strengths of group-specific pathways to link social health and activity behaviors to quality of life will be compared using the chi-square (χ2) difference test of model fit.

    Up to 1 year

  • Moderation effect of health status

    Moderation effect is analyzed by the interaction between the independent variable (X), and the moderator variable (Y) in a regression model, where the endpoint is the dependent variable (Z). Moderation effect is the endpoint itself, indicated by the significance of the interaction term's regression coefficient (B3), which shows how the relationship between X and Y changes depending on the level of Z. 'X' is social health, physical activity, and quality of life. 'Y' is health status. 'Z' is moderation effect. The strengths of group-specific pathways to link social health and activity behaviors to quality of life will be compared using the chi-square (χ2) difference test of model fit.

    Up to 1 year

Study Arms (1)

Observational (actigraph, surveys)

Patients complete surveys and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.

Other: Medical Device Usage and EvaluationOther: Quality-of-Life AssessmentOther: Survey Administration

Interventions

Wear an actigraph GT3X-BT accelerometer

Observational (actigraph, surveys)

Complete survey

Also known as: Quality of Life Assessment
Observational (actigraph, surveys)

Complete survey

Observational (actigraph, surveys)

Eligibility Criteria

Age18 Years - 39 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed and/or treated with cancer between ages 18-39 at University of Southern California (USC) hospitals.

You may qualify if:

  • Diagnosed and/or treated with cancer between ages 18-39 at USC hospitals.
  • Cancer types prototypical for adolescents and young adults (AYAs) and cancer stages I-III; select patients with stage IV disease may be eligible, with approval by the principal investigator (PI) and in consultation with the treating clinician.
  • Must be within three months of a de novo cancer diagnosis at recruitment and on/indicated for curative therapy (any modality). Patients may continue on adjuvant therapy throughout duration of the study.
  • Patients must have anticipated survival of \>1-year at time of diagnosis.

You may not qualify if:

  • Diagnosis of blood malignancies such as leukemias (these cancers have divergent treatment patterns of longer duration than other cancers and are more commonly pediatric cancers). Some early stage lymphomas with favorable prognoses may be eligible, with approval by the PI and in consultation with the treating clinician.
  • Primary language other than English or Spanish.
  • Inability to complete a survey and/or wear an accelerometer either per the patient or in consultation with the clinician's judgment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States

RECRUITING

MeSH Terms

Conditions

Central Nervous System NeoplasmsHodgkin DiseaseBone NeoplasmsBrain NeoplasmsTesticular NeoplasmsLymphoma, Non-HodgkinUterine Cervical NeoplasmsColorectal NeoplasmsOvarian NeoplasmsCarcinoma, Medullary

Condition Hierarchy (Ancestors)

Nervous System NeoplasmsNeoplasms by SiteNeoplasmsNervous System DiseasesLymphomaNeoplasms by Histologic TypeLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesBone DiseasesMusculoskeletal DiseasesBrain DiseasesCentral Nervous System DiseasesEndocrine Gland NeoplasmsGenital Neoplasms, MaleUrogenital NeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital DiseasesEndocrine System DiseasesTesticular DiseasesGonadal DisordersUterine NeoplasmsGenital Neoplasms, FemaleUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesOvarian DiseasesAdnexal DiseasesCarcinoma, NeuroendocrineNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms, Ductal, Lobular, and MedullaryNeoplasms, Nerve Tissue

Study Officials

  • Kimberly Miller, PhD

    University of Southern California

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kimberly A Miller, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 14, 2021

First Posted

December 2, 2025

Study Start

November 24, 2021

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2027

Last Updated

December 2, 2025

Record last verified: 2025-11

Locations